The EORTC Brain Tumor Group and Protagen AG announce their collaboration to investigate the immuno-competence of long-term Glioblastoma survivors
Zurich, Switzerland and Dortmund, Germany – 4 December 2018 – The European Organization for Research and Treatment of Cancer (EORTC) Brain Tumor Group and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify autoantibody biomarkers that investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors. Glioblastoma is the most... Read more